Faecal calprotectin as a marker for oesophago-gastric cancer

Vincent, Zoe; Hornby, Steve; Ball, Susan; Sanders, Grant; Ayling, Ruth M

doi:10.1177/0004563215578191

Cited by 12 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Negretti et al (2020) used a porcine-ligated loop model to study the porcine intestinal response to Campylobacter jejuni infection and found that the abundance of inflammatory cytokines IL -8 and TNF -α were substantially increased during infection. Vincent et al (2015) used calmodulin in stool as a marker of inflammatory diseases. S100A9 amplifies inflammatory responses’ and plays a key point in the involvement of organisms in immune-related responses ( Vincent et al, 2015 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Decreased S100A9 expression alleviates Clostridium perfringens beta2 toxin-induced inflammatory injury in IPEC-J2 cells

Huang

Xie

et al. 2023

PeerJ

View full text Add to dashboard Cite

Background S100 calcium-binding protein A9 (S100A9) is a commonly known pro-inflammatory factor involved in various inflammatory responses. Clostridium perfringens (C. perfringens ) type C is known to cause diarrhea in piglets. However, the role of S100A9 in C. perfringens type C-induced infectious diarrhea is unclear. Methods Here, the S100A9 gene was overexpressed and knocked down in the IPEC-J2 cells, which were treated with C. perfringens beta2 (CPB2) toxin. The role of S100A9 in CPB2 toxin-induced injury in IPEC-J2 cells was assessed by measuring the levels of inflammatory cytokines, reactive oxygen species (ROS), lactate dehydrogenase (LDH), cell proliferation, and tight junction-related proteins. Results The results showed elevated expression of S100A9 in diarrhea-affected piglet tissues, and the elevation of S100A9 expression after CPB2 toxin treatment of IPEC-J2 was time-dependent. In CPB2 toxin-induced IPEC-J2 cells, overexpression of S100A9 had the following effects: the relative expression of inflammatory factors IL-6, IL8, TNF-α, and IL-1β was increased; the ROS levels and LDH viability were significantly increased; cell viability and proliferation were inhibited; the G0/G1 phase cell ratio was significantly increased. Furthermore, overexpression of S100A9 reduced the expression of tight junction proteins in CPB2-induced IPEC-J2 cells. The knockdown of S100A9 had an inverse effect. In conclusion, our results confirmed that S100A9 exacerbated inflammatory injury in CPB2 toxin-induced IPEC-J2 cells, inhibited cell viability and cell proliferation, and disrupted the tight junctions between cells. Thus, decreased S100A9 expression alleviates CPB2 toxin-induced inflammatory injury in IPEC-J2 cells.

show abstract

Section: Discussionmentioning

confidence: 99%

“… Vincent et al (2015) used calmodulin in stool as a marker of inflammatory diseases. S100A9 amplifies inflammatory responses’ and plays a key point in the involvement of organisms in immune-related responses ( Vincent et al, 2015 ). The ROS levels in the intestine can cause various problems ( Wang et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Decreased S100A9 expression alleviates Clostridium perfringens beta2 toxin-induced inflammatory injury in IPEC-J2 cells

Huang

Xie

et al. 2023

PeerJ

View full text Add to dashboard Cite

show abstract

“…Similarly, a meta‐analysis concluded that the overall sensitivity and specificity of fecal calprotectin in the diagnosis of colorectal cancer were 36 and 71%, and that it was not recommended as a screening test for colorectal malignancies in the general population . Among 39 patients with known esophageal gastric cancer and 191 control subjects, fecal calprotectin had a sensitivity of 76.9% and a specificity of 88.0% in the diagnosis of esophageal gastric cancer, using the manufacturer’s cut‐off value <50 mg/g . Our previous studies have shown that fecal BAFF was elevated in IBD patients, but its role in gastrointestinal cancer is still unknown.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic value of fecal B cell activating factor in patients with abdominal discomfort

Xie

Quan

Wang

et al. 2019

Clinical &Amp; Experimental Immunology

View full text Add to dashboard Cite

Summary Fecal calprotectin has successfully been widely recommended as a sensitive biomarker of inflammatory bowel diseases (IBD). Recently, we have identified an excellent new fecal biomarker, B cell activating factor (BAFF), as being as effective as fecal calprotectin for diagnosing intestinal inflammation. In this study, a total of 230 patients with abdominal discomfort were prospectively enrolled and fecal samples were collected within 24 h before the endoscopic examinations. We show that fecal BAFF levels were significantly higher in patients with ulcerative colitis (median = 1549 pg/g, P < 0·0001), Crohn’s disease (median = 735 pg/g, P < 0·0001), gastric cancer (median = 267 pg/g, P < 0·0001) and colorectal cancer (median = 533 pg/g, P < 0·0001) than those in healthy groups (median = 61 pg/g), while the values of which in patients with gastric polyps, colorectal polyps, esophagitis/gastritis/duodenitis and peptic ulcer were in the range of healthy individuals (P > 0·05). An optimal cut‐off value at 219·5 pg/g of fecal BAFF produced sensitivity, specificity, positive predictive and negative predictive values of 85, 91, 84 and 92%, respectively, for IBD or carcinoma. Our results therefore indicate a potential role for fecal BAFF as a sensitive screening parameter for IBD and gastrointestinal carcinoma, as well a useful tool to select patients with abdominal discomfort for further endoscopic examinations.

show abstract

“…diseases and malignancies have been discussed [26][27][28][29][30][31][32]. To the best of our knowledge, no similar study has been performed on fecal calprotectin level in patients with MM, so this study was designed to revealed the possible association.…”

Section: Plos Onementioning

confidence: 99%

Calprotectin as new potential clinical marker for multiple myeloma

et al. 2023

View full text Add to dashboard Cite

Increased levels of inflammatory cytokines in multiple myeloma (MM) patients and the role of inflammation in disease pathogenesis, have recently been considered. The aim of this study was to quantitatively evaluation of fecal calprotectin (CP) as a non-invasive biomarker for the evaluation of inflammation in patients with multiple myeloma. This study is a hospital-based case control study. MM patients referred to patients referred to medical centers of Tehran province, Iran, were identified and classified into two groups of new MM patients (n = 40) and patients undergoing treatment (n = 28). Healthy individuals were included in the study as healthy control (n = 25). Morning stool samples were collected and CP was extracted immediately. After collecting the samples, CP was measured according to ELISA method and was determined in μg/g of feces. Values above 50 μg/g of feces are positive and indicate inflammation. The results revealed that there is a significant difference between groups in terms if CP mean (p = 0.001). The mean of CP among new cases, under treatment and control groups were 301.3 (SD: 141.0), 165.1 (SD: 153.9) and 36.9 (SD: 13.5), respectively. Then the groups were compared in pairs, the results showed that the new case group was significantly different from the under-treatment group (p = 0.001), and also the control group showed a significant difference with the new case group (p = 0.001) and the under-treatment group (p = 0.001) that the amount of CP in the control group was significantly lower than the other two groups. In addition, the results of the study showed a significant correlation between age and plasma cells with CP value, so that with increasing age and plasma cells, CP value also showed a significant increase. The results indicate that quantitative evaluation of CP as a non-invasive laboratory biomarker has a high potential as a clinical marker in patients with multiple myeloma and inflammation should considered as a hallmark of cancer. Further diagnostic studies are recommended.

show abstract

Faecal calprotectin as a marker for oesophago-gastric cancer

Cited by 12 publications

References 20 publications

Decreased S100A9 expression alleviates Clostridium perfringens beta2 toxin-induced inflammatory injury in IPEC-J2 cells

Decreased S100A9 expression alleviates Clostridium perfringens beta2 toxin-induced inflammatory injury in IPEC-J2 cells

Diagnostic value of fecal B cell activating factor in patients with abdominal discomfort

Calprotectin as new potential clinical marker for multiple myeloma

Contact Info

Product

Resources

About